The court ruled in favor of Novo Nordisk and the FDA, rejecting a compounding pharmacy group's attempt to stop the FDA's ...

Eli Lilly (NYSE:LLY) is a pharmaceutical titan with an $815 billion market cap, putting it on track to be the next $1 ...

A new weight loss drug that's being trialled as a daily pill and could rival Ozempic has delivered some astonishing results.

GLP-1 medications have been going viral for their transformative effects, but now people are raising concerns about a ...

Drug distributors like Cardinal Health, Cencora and McKesson will play a key role in the drug supply chain, improving patient ...

Shares in Eli Lilly shot up last Thursday after the US pharma major announced positive top-line Phase III results from ...

Eli Lilly ( LLY 0.89%) has been growing its sales at a good clip over the past year. This is partly thanks to Zepbound, a ...

The prospect of a pill rather than an injection is obviously appealing to some people, but will fear of needles be enough to ...

After selling off a portion of its diabetes care business last year, Ypsomed is now fully exiting the diabetes care business ...

Given the potential opportunities in the sector, should investors buy Eli Lilly stock? Here's where the company and its stock ...

Novo Nordisk stock popped Tuesday on reports it's asked the FDA to approve its weight-loss pill, an oral version of Wegovy.

The FDA has received six adverse event reports connected to this specific lot of Ozempic (all submitted by Novo Nordisk), but ...